Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Sagimet Biosciences Inc. - Series A Common Stock (NQ:SGMT)

7.655 +0.005 (+0.07%)
Streaming Delayed Price Updated: 9:37 AM EDT, May 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 15,143
Open 7.620
Bid (Size) 7.670 (1,300)
Ask (Size) 7.700 (600)
Prev. Close 7.650
Today's Range 7.570 - 7.670
52wk Range 3.080 - 11.41
Shares Outstanding 30,674,855
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire

Performance

YTD
+27.8%
+27.8%
1 Month
+41.2%
+41.2%
3 Month
+35.7%
+35.7%
6 Month
-9.9%
-9.9%
1 Year
+131.3%
+131.3%

More News

Read More
News headline image
Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
From Sagimet Biosciences Inc.
Via GlobeNewswire
Unusual volume stocks are being observed in Tuesday's session. ↗
Via Chartmill
These stocks are moving in today's session ↗
Via Chartmill
Top stock movements in today's session. ↗
Via Chartmill
News headline image
Why Sagimet Biosciences Stock Is Soaring Today ↗
Via The Motley Fool
These stocks are gapping in today's session ↗
Via Chartmill
Top movers in Monday's pre-market session ↗
Via Chartmill
News headline image
Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Provides Strategic and Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Appointment of Andreas Grauer, MD, as Chief Medical Officer
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Poster and Oral Presentations at the Fueling MASH: Metabolic Drivers and Inflammatory Crosstalk Keystone Symposium and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Participation in Three Upcoming Investor Conferences
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
From Sagimet Biosciences Inc.
Via GlobeNewswire
Tuesday's session: gap up and gap down stocks ↗
Via Chartmill
News headline image
Sagimet Announces Positive 52-Week Data from License Partner Ascletis’ Open-Label Phase 3 Clinical Trial Evaluating the Long-Term Safety of ASC40 (Denifanstat) Tablets in Patients with Moderate to Severe Acne
From Sagimet Biosciences Inc.
Via GlobeNewswire
Get insights into the top gainers and losers of Thursday's after-hours session. ↗
Via Chartmill
News headline image
Sagimet Biosciences Announces Poster Presentation at the 10th Annual MASH-TAG 2026 Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Positive Results from the Phase 1 PK Clinical Trial of Denifanstat and Resmetirom Combination
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences and TAPI Announce Global License Agreement for Innovative Forms of Resmetirom API for Sagimet’s Fixed Dose Combination Program
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet’s License Partner Ascletis Announced Acceptance of New Drug Application for Denifanstat for the Treatment of Moderate to Severe Acne by China’s National Medical Products Administration
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Sagimet Biosciences Inc.
Via GlobeNewswire
News headline image
Sagimet Biosciences to Participate in the 8th Annual Evercore ISI Healthcare Conference
From Sagimet Biosciences Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Sagimet Biosciences Inc. - Series A Common Stock publicly traded?
Yes, Sagimet Biosciences Inc. - Series A Common Stock is publicly traded.
What exchange does Sagimet Biosciences Inc. - Series A Common Stock trade on?
Sagimet Biosciences Inc. - Series A Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock?
The ticker symbol for Sagimet Biosciences Inc. - Series A Common Stock is SGMT on the Nasdaq Stock Market
What is the current price of Sagimet Biosciences Inc. - Series A Common Stock?
The current price of Sagimet Biosciences Inc. - Series A Common Stock is 7.655
When was Sagimet Biosciences Inc. - Series A Common Stock last traded?
The last trade of Sagimet Biosciences Inc. - Series A Common Stock was at 05/13/26 09:37 AM ET
What is the market capitalization of Sagimet Biosciences Inc. - Series A Common Stock?
The market capitalization of Sagimet Biosciences Inc. - Series A Common Stock is 234.82M
How many shares of Sagimet Biosciences Inc. - Series A Common Stock are outstanding?
Sagimet Biosciences Inc. - Series A Common Stock has 235M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.